Agency IQ

DECEMBER 1, 2023

What We Expect the FDA to do in December 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Regulations Production 40

Agency IQ

OCTOBER 27, 2023

What We Expect the FDA to do in November 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

MAY 14, 2021

Their waists got smaller… They also saw an improvement in fat-regulating hormones. A little over a month later… A package arrived at my door… I ripped open the box as fast as I could. And serves as your body’s “master regulating switch.” When the package gets dropped off at your door….

Packaging 52

Packaging Production Research Doctors 52

The Pharma Data

MAY 13, 2021

Then these hormones can’t regulate your metabolism like they should…. In a major double-blind clinical trial published in the American College of Endocrinology…. Numerous double-blind, randomized, and placebo-controlled trials have also found Rhodiola to…. It was like the floodgates burst wide open…. So what’s the fix here?

Production 52

Production Packaging Doctors Research 52

Agency IQ

JULY 28, 2023

October 1, 2023 [link] Regulations Expected to be Published in Q3These are taken from the most recent version of the White House’s Unified Agenda. Specifically, this ANPRM seeks comments, research, information, data, and responses from certain categories of stakeholders that can inform the Agency’s modernization of FDA’s recall regulation.

FDA 40

FDA Science Biosimilars Regulations 40

Drug & Device Law

DECEMBER 29, 2023

2023) (remote trial testimony cannot be compelled beyond Rule 45’s 100-mile limit on subpoenas) ( here ); Carson v. They excluded bogus expert testimony under Fed. Further, “adequacy” is an objective standard, that neither a plaintiff’s self-interested testimony nor equivocal health care provider testimony can touch.

Testimonials 105

Testimonials FDA Drugs Vaccine 105